Dr. Kim Agnew (Hon BSc, BVSc, MACVSc) has 25 years of experience in the animal health industry with business development, product development, regulatory affairs, clinical research, technical support and pharmacovigilance. After working for 10 years in mixed animal veterinary practice in New Zealand with a focus on the dairy and swine industries, Dr. Agnew entered the animal health industry in 1995. Roles in this sector have involved management of research and regulatory affairs, regional regulatory management, and leadership of a global R&D research hub.
Dr. Agnew worked for 20 years at Elanco Animal Health in a variety of management roles including Research and Regulatory Manager, Innovation Manager and Associate Director of Research and Development. Following this, he worked for 5 years at Merial, now Boehringer Ingelheim, as the Research and Development Leader of a specialized group executing the development of incremental innovation for ruminant markets in Australia and New Zealand. Capabilities of this group ranged from ground-up formulation development to proposed product market assessments, clinical study designs and execution, and preparation of required regulatory dossiers for submission.
Dr. Agnew has extensive expertise working and collaborating with the Agricultural Compounds and Veterinary Medicines (ACVM) Agency and the Environmental and Risk Management Agency (ERMA), now the Environmental Protection Authority (EPA), in New Zealand, as well as the Australian Pesticides and Veterinary Medicines Authority (APVMA). He has served on key regulatory industry bodies linked to Animal Medicines Australia, and is a former President of the Australian Vets in Industry Special Interest Group (SIG) of the Australian Veterinary Association (AVA). He has also collaborated with industry and government groups during stakeholder discussions regarding the potential introduction of contentious technologies to the Australian and New Zealand markets.
From a regulatory submission perspective, Dr. Agnew has submitted and negotiated a variety of successful approvals including Rumensin drenchable liquid and trough treatment for dairy cattle, Extinosad suspension concentrate and pour-on for sheep, Cyrex for sheep, Comfortis (spinosad) for dogs, Pulmotil (tilmocosin) for swine, Demize for cattle, and Micotil for cattle. From a product development perspective, Dr. Agnew has a passion for the development and commercialization of new products to improve animal health and welfare, and farmer productivity. Over the years, he has developed a strong understanding of the business development and market research processes required to successfully commercialize technologies, including the development/ conduct of research plans and studies to fulfill local and global regulatory requirements. As both a team lead and contributor, Dr. Agnew has been involved in the ground-up development and commercialization of 15 new products, numerous line extensions to existing products, and is named in 6 product development patents.
Furthermore, Dr. Agnew has developed a broad network across various Universities in Australia, and has been instrumental in gaining industry support for multiple Australian Research Council (ARC) Linkage Grant collaborations and research projects leveraging the very high quality of science research available in Australia and New Zealand. Active projects remain confidential.